jeudi 29 janvier 2015
MedDay Notes Acceptance of Manuscript into Journal of Multiple Sclerosis and Related Disorders
Paris, January 29 2015 - MedDay, an emerging biotechnology company focused on the treatment of nervous system disorders, today notes the acceptance of a manuscript relating to results from a pilot study to assess the clinical efficacy and safety of high doses of biotin in patients suffering from progressive Multiple Sclerosis (MS). Biotin is a vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acids synthesis.
The manuscript, entitled “High doses of biotin in chronic progressive multiple sclerosis: a pilot study”, has been accepted into the Journal of Multiple Sclerosis and Related Disorders. For more information on the study, please see: www.msard-journal.com/article/S2211-0348(15)00006-1/abstract.
The conclusions were that the preliminary data suggest that high doses of biotin may impact disease's progression and improve clinical sequelae in primary and secondary progressive MS. To date, no drug has been found to have any impact on progressive MS.
Two multi-centric double-blind placebo-controlled trials are currently underway using MedDay’s lead candidate, MD1003, a highly concentrated formulation of D biotin for the treatment of primary and secondary progressive MS. MedDay expects to complete its first pivotal study in Q1 2015. A second pivotal study is on track for completion by the end of 2015.
MedDay is a biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer) who has 25 years of experience in drug development and clinical research in the pharmaceutical industry. In April 2013, InnoBio, a biotechnology fund managed by BPIFrance, and Sofinnova Partners together invested in MedDay. The Company’s most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis. MD1003 is currently being investigated in 2 pivotal phase III studies in France, involving 250 patients. The first patient was included in October 2013 and the Company expects to announce the data from the MD1003 studies in 2015. For more information, please see: www.medday-pharma.com.
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott, Jonathan Birt, Ivar Milligan, Laura Thornton
Tel: +44 (0)20 3709 5700